Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
Fragoso Y D, Adoni T, Alves-Leon S V, Apostolos-Pereira S L, de Araujo Y R, Becker J, Brooks J B B, Correa E C, Damasceno A, de Albuquerque Damasceno C A, et al.
Expert Rev Clin Pharmacol. 2016 Jan 21. PMID: 26794493.Abstract